Pharmacogenetics and rational drug use around the world

Pharmacogenomics

Volumn 12, Issue 6, 2011, Pages 897-905

  Roederer, Mary W ^a   Sanchez Giron, Francisco ^b   Kalideen, Kusha ^c   Kudzi, William ^d   McLeod, Howard L ^a   Zhang, Wei ^e  

^a UNC Hamner Institute for Drug Safety Sciences   (United States)

^b INSTITUTO NACIONAL DE MEDICINA GENÓMICA   (Mexico)

^c UNIVERSITY OF CAPE TOWN   (South Africa)

^d UNIVERSITY OF GHANA   (Ghana)

^e CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

China; CYP2C19; CYP2C9; CYP2D6; Ghana; medical decision making; Mexico; N acetyltransferase; national formulary; PGENI; pharmacogenetics; Pharmacogenetics for Every Nation Initiative; pharmacovigilance; South Africa; WHO

Indexed keywords

ABACAVIR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBAMAZEPINE; CODEINE; CYTOCHROME P450 2D6; HLA B57 ANTIGEN; ISONIAZID; TAMOXIFEN;

BREAST CANCER; DRUG ACETYLATION; DRUG CHOICE; DRUG DISPOSITION; DRUG EFFICACY; DRUG FORMULARY; DRUG HYPERSENSITIVITY; DRUG METABOLISM; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG USE; EDUCATION PROGRAM; EVIDENCE BASED MEDICINE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HEALTH CARE ACCESS; HUMAN; HYPERTENSION; LIVER TOXICITY; MEDICAL DECISION MAKING; MORTALITY; PAIN; PHARMACOGENETICS; REVIEW; TUBERCULOSIS;

COST-BENEFIT ANALYSIS; DEVELOPING COUNTRIES; DRUG THERAPY; EVIDENCE-BASED MEDICINE; HEALTH POLICY; HUMANS; PHARMACOGENETICS; POPULATION GROUPS; WORLD HEALTH ORGANIZATION;

EID: 79959449698     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.11.17     Document Type: Review

References (32)

1. Hogerzeil HV: The concept of essential medicines: lessons for rich countries. BMJ 329(7475), 1169-1172 (2004). (Pubitemid 39524781)
2. Laing R, Waning B, Gray A et al.: 25 years of the WHO essential medicines lists: progress and challenges. Lancet 361(9370), 1723-1729 (2003). (Pubitemid 36577449)
3. WHO: The selection of essential drugs: report of a WHO expert committee. World Health Organ. Tech. Rep. Ser. 615, 1-36 (1977).
4. Frueh FW, Amur S, Mummaneni P et al.: Pharmacogenomic biomarker information in drug labels approved by the United States Food and Drug Administration: prevalence of related drug use. Pharmacotherapy 28(8), 992-998 (2008).
5. Yen-Revollo JL, van Booven DJ, Peters EJ et al.: Influence of ethnicity on pharmacogenetic variation in the Ghanaian population. Pharmacogenomics J. 9(6), 373-379 (2009).
6. Holm S: Pharmacogenetics, race and global injustice. Dev. World Bioeth. 8(2), 82-88 (2008).
7. Wayengera M, Kajumbula H, Byarugaba W: Harnessing pharmacogenomics to tackle resistance to the 'nucleoside reverse trancripatse inhibitor' backbone of highly active antiretroviral therapy in resource limited settings. Open AIDS J. 2, 78-81 (2008).
8. Marsh S, van Booven DJ, McLeod HL: Global pharmacogenetics: giving the genome to the masses. Pharmacogenomics 7(4), 625-631 (2006). (Pubitemid 43891418)
9. Roederer MW, McLeod HL: Applying the genome to national drug formulary policy in the developing world. Pharmacogenomics 11(5), 633-636 (2010).
10. He J, Gu D, Wu X et al.: Major causes of death among men and women in China. N. Engl. J. Med. 353(11), 1124-1134 (2005). (Pubitemid 41317435)
11. Califf RM: The need for a national infrastructure to improve the rational use of therapeutics. Pharmacoepidemiol. Drug Saf. 11(4), 319-327 (2002). (Pubitemid 34704732)
12. Lim KS, Kwan P, Tan CT: Association of HLA-B*1502 allele and carbamazepine-induced severe adverse cutaneous drug reaction among Asians, a review. Neurol. Asia 13, 15-21 (2008).
13. Mallal S, Phillips E, Carosi G et al.: HLA-B*5701 screening for hypersensitivity to abacavir. N. Engl. J. Med. 358(6), 568-579 (2008).
14. Saag M, Balu R, Phillips E et al.: High sensitivity of human leukocyte antigen-b*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients. Clin. Infect. Dis. 46(7), 1111-1118 (2008). (Pubitemid 351589880)
15. Ingelman-Sundberg M, Sim SC, Gomez A et al.: Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol. Ther. 116(3), 496-526 (2007). (Pubitemid 350116943)
16. Zhou SF, Zhou ZW, Huang M: Polymorphisms of human cytochrome P450 2C9 and the functional relevance. Toxicology 278(2), 165-188 (2009).
17. Klein TE, Altman RB, Eriksson N et al.: Estimation of the warfarin dose with clinical and pharmacogenetic data. N. Engl. J. Med. 360(8), 753-764 (2009).
18. Ferreira P, Cavaco I, Gil J: Pharmacogenetic tools for malaria and TB in the developing world. Per. Med. 5(6), 627-639 (2008).
19. Huang YS, Chern HD, Su WJ et al.: Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis. Hepatology 35(4), 883-889 (2002).
20. Hughes AR, Mosteller M, Bansal AT et al.: Association of genetic variations in HLA-B region with hypersensitivity to abacavir in some, but not all, populations. Pharmacogenomics 5(2), 203-211 (2004). (Pubitemid 38351278)
21. Rabie H, Henning KL, Schoeman P et al.: Abacavir: its use and hypersensitivity. S. Afr. J. HIV Med. 10(4), 81-84 (2009).
22. Hogerzeil HV: Promoting rational prescribing: an international perspective. Br. J. Clin. Pharmacol. 39(1), 1-6 (1995).
23. Higgs JE, Andrews J, Gurwitz D et al.: Pharmacogenetics education in British medical schools. Genomic Med. 2(3-4), 101-105 (2008).
24. Thurston VC, Wales PS, Bell MA et al.: The current status of medical genetics instruction in US and Canadian medical schools. Acad. Med. 82(5), 441-445 (2007). (Pubitemid 46684405)
25. Murphy JE, Green JS, Adams LA et al.: Pharmacogenomics in the curricula of colleges and schools of pharmacy in the United States. Am. J. Pharm. Educ. 74(1), 7 (2010).
26. Hardy BJ, Seguin B, Goodsaid F et al.: The next steps for genomic medicine: challenges and opportunities for the developing world. Nat. Rev. Genet. 9(Suppl. 1), S23-S27 (2008).
27. Coloma J, Harris E: Molecular genomic approaches to infectious diseases in resource-limited settings. PLoS Med. 6(10), e1000142 (2009).
28. Kitada M: Genetic polymorphism of cytochrome P450 enzymes in Asian populations: focus on CYP2D6. Int. J. Clin. Pharmacol. Res. 23(1), 31-35 (2003). (Pubitemid 37339363)
29. Xie HG, Prasad HC, Kim RB et al.: CYP2C9 allelic variants: ethnic distribution and functional significance. Adv. Drug Deliv. Rev. 54(10), 1257-1270 (2002). (Pubitemid 35284252)
30. Liu ZQ, Mo W, Huang Q et al.: Genetic polymorphisms of human b-adrenergic receptor genes and their association with obesity. Zhong Nan Da Xue Xue Bao Yi Xue Ban 32(3), 359-367 (2007).
31. Wang JL, Li X, Hao PP et al.: Angiotensin II type 1 receptor gene A1166C polymorphism and essential hypertension in Chinese: a meta-analysis. J. Renin Angiotensin Aldosterone Syst. 11(2), 127-135 (2010).
32. Ji LD, Zhang LN, Shen P et al.: Association of angiotensinogen gene M235T and angiotensin-converting enzyme gene I/D polymorphisms with essential hypertension in Han Chinese population: a meta-analysis. J. Hypertens. 28(3), 419-428 (2010).